<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102437">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799460</url>
  </required_header>
  <id_info>
    <org_study_id>ShanghaiMEC-2011</org_study_id>
    <secondary_id>11YZ65</secondary_id>
    <nct_id>NCT01799460</nct_id>
  </id_info>
  <brief_title>Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy</brief_title>
  <official_title>Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analysis the different genotype in the idiopathic membranous
      nephropathy patients which with different therapeutic outcomes after treated by the
      Comprehensive Treatment Regimen or immunosuppressive agents, and so as to looking for ideal
      markers to assess appropriate treatment approach and the long-term efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to looking for the gene level predictors in the
      patients who suffered from idiopathic membranous nephropathy. And according to the
      predictors, the clinicians could make a decision which method should be taken on IMN
      patients, Traditional Chinese Medicine or western medicine, and could get better results.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Genome-wide single-nucleotide-polymorphism of IMN patients treated by the Comprehensive Treatment Regimen or conventional approach</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Screening for single-nucleotide-polymorphism as the prognostic factor for the TCM intervention of IMN patients.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>CR/CTR group</arm_group_label>
    <description>The complete remission group treated by the Comprehensive Treatment Regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NR/CTR group</arm_group_label>
    <description>The non-remission group treated by the Comprehensive Treatment Regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CR/IA group</arm_group_label>
    <description>The complete remission group treated by Immunosuppressive Agents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NR/IA group</arm_group_label>
    <description>The non-remission group treated by Immunosuppressive Agents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The Comprehensive Treatment Regimen of Traditional Chinese Medicine</intervention_name>
    <description>①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day
②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.
③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily.</description>
    <arm_group_label>CR/CTR group</arm_group_label>
    <arm_group_label>NR/CTR group</arm_group_label>
    <other_name>ShenQiMoShen Decoction</other_name>
    <other_name>HuoXueTongMai Capsule</other_name>
    <other_name>HeiLiaoDou Particle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The immunosuppressive agents</intervention_name>
    <description>According to Kidney  Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis</description>
    <arm_group_label>CR/IA group</arm_group_label>
    <arm_group_label>NR/IA group</arm_group_label>
    <other_name>Glucocorticoid</other_name>
    <other_name>Cyclosporine</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        idiopathic membranous nephropathy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of idiopathic membranous nephropathy

          -  Chronic Kidney Disease (CKD)≤3 stage（Glomerular Filtration Rate (GFR)≥30ml/min）and 24
             hour urinary protein≥3g

          -  Voluntarily participated in the study and signed an informed consent

        Exclusion Criteria:

          -  Combined life-threatening complications such as serious infection

          -  Abnormal glucose metabolism

          -  Patients with malignant tumors or malignancy , HIV infection and a history of mental
             illness , acute central nervous system disease , serious gastrointestinal
             diseases,etc

          -  Pregnancy or breast-feeding women

          -  Undergoing other clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Lin, PHD,MD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Lin, PHD</last_name>
    <phone>86-13816583673</phone>
    <email>happytlynn@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Lin, PHD</last_name>
      <phone>86-13816583673</phone>
      <email>happytlynn@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>single-nucleotide-polymorphism</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>the Comprehensive Treatment Regimen</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
